Newsroom_MEDOMICS MEDICAL - Tests for life!

News

Focus on the diagnosis of pathogenic microorganisms in the reproductive tract and respiratory tract

2023 American AACC

2023

Antimicrobial resistance (AMR) poses a serious global threat of growing concern to human, animal, and environment health. This is due to the emergence, spread, and persistence of multidrug-resistant (MDR) bacteria or “superbugs.”

2023

Medomics has launched Candida albicans/ Trichomonas vaginalis/ Gardnerella vaginalis antigen Combo Test Kit (LFIA)

Reproductive tract infection is an important part of systemic infection and has become a major public health problem in the world. Recent studies have shown that reproductive tract infection is closely related to tumor occurrence, infertility, ectopic pregnancy, premature rupture of membranes and premature delivery and so on. Almost all reproductive tract infections are accompanied by changes of genital tract microenvironment. There are several common pathogens which are easy to cause gynecologic diseases in women: 1)Candida albicans is a major fungal pathogen of humans. It exists as a commensal in the oral cavity, gut or genital tract of most individuals, constrained by the local microbiota, epithelial barriers and immune defenses. Their perturbation can lead to fungal outgrowth and the development of mucosal infections such as oropharyngeal or vulvovaginal candidiasis, and patients with compromised immunity are susceptible to life-threatening systemic infections. 2)Trichomonas vaginalis is a motile organism with a size comparable to a white blood cell. It has at least 4 flagella that provide undulating motility. The organism resides in the lumen of the urogenital tract. The organism releases cytotoxic proteins that destroy the epithelial lining. During an infection, the vaginal pH usually increases. 3)Gardnerella vaginalis is an anaerobic bacterium that resides in the normal vaginal flora. Normally, vaginal flora is predominated by the lactobacilli species, but when organisms such as gardnerella begin to overgrow and become the dominant species, this leads to bacterial vaginosis (BV). Bacterial vaginosis is characterized by the presence of clue cells, which are epithelial cells of the cervix that are covered with rod-shaped bacteria. According to statistics, 11% of women have BV detected during physical examination, and 36% - 60% among vaginitis patients in gynecological clinics. To meet the needs of market, Jiangsu Medomics Medical Technology Co., Ltd. has released a new product named Candida albicans/Trichomonas vaginalis/Gardnerella vaginalis antigen Combo Test Kit (LFIA). The test kit uses a double antibody sandwich method to detect Candida albicans, Trichomonas vaginalis, and Gardnerella vaginalis by latex microsphere immunochromatography, and is suitable for women with clinical symptoms of gynecological inflammation or suspected gynecological inflammation. The products have following advantages: On-site screening & quick results in 15 mins Low professional and training requirement Unaffected by medication Obtain pathogen antigen with high specificity Please CONTACT us if you are interested. We will be ready to provide you with the best possible service.

2023

2023 Dubai MEDLAB

2023

Medomics at Medlab 2023

2023

Medomics has released KPC/IMP/NDM/VIM/OXA-48 Combo Test Kit

KPC/IMP/NDM/VIM/OXA-48 Combo Test Kit

2022

Medomics at MEDICA 2022

Medomics will attend Düsseldorf International Medical Fair in Germany in Nov. 14th - 17th, 2022. MEDICA is the leading international trade fair for medical sector. It is a very attractive event: more than 5100 exhibitors from 66 nations.

2022

Medomics Medical contributes to global epidemic prevention and control, and has been approved two more certifications

On June 28, 2022, Medomics Medical successfully obtained the TGA SARS-CoV-2 Antigen Test Kit (LFIA) Product Self-Test Certificate. This is the third certificate that Medomics Medical has obtained for this rapid test combo products in the Australian market after the professional version and the saliva oral self-test version.

2022

< 1 2 3 4 5 >

Jiangsu Medomics Medical Technology Co., Ltd.

Tel: 86 025-58601060

E-mail: overseas@medomics-dx.com

Address: Building 01, Phase 6, No.71, Xinghui Road, Jiangbei New Area, Nanjing, China

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

All products sold on this website are for scientific research only